^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | MT-5111 (HER2 inhibitor, Protein synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results
Published date:
05/26/2022
Excerpt:
Part B expansion cohorts for HER2+ breast cancer (BC), gastroesophageal adenocarcinoma (GEA),...Best response per RECIST thus far was stable disease (SD) in 7 pts or non-CR/non-PD in 2 pts: 1 pt had SD for 12 weeks (wks) (4.5 μg/kg, pancreatic CA); 1 pt (1 μg/kg/dose, BC) had non-CR/non-PD for 30 wks; 1 pt (10 μg/kg/dose, GEA) has ongoing SD for 18 wks.
DOI:
10.1200/JCO.2022.40.16_suppl.2583
Trial ID:
